The Global Drug sales of Stelara stood at USD 9,723 Millions in 2022
The indicator recorded a historical growth (CAGR) of14% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to decline at a CAGR of...
Ustekinumab (Stelara) is a human monoclonal antibody used as immunosuppressant. It is produced by a recombinant DNA technology. It is formulated as an injectable solution for injection, powder for solution and solution for injection in pre-filled syringe and is administered by subcutaneous route and intravenous administration and injectable concentrate solution for subcutaneous route of administration.
Mechanism of Action
Ustekinumab is a human IgG1 kappa monoclonal antibody that binds with high affinity and specificity to the IL-12 subunit beta used by both the interleukin (IL)-12 and IL-23 cytokines. In variety of chronic inflammatory conditions IL-12 and IL-23 were implicated to play a role in the initiation of inflammation. p40 subunit is a component of both interleukin-12 (Th1) and interleukin-23 (Th17). Inhibition of the IL-12/23 signaling pathway leads to profound suppression of both the Th1 and Th17 cell lineage of cytokines and chemokines and their inflammatory pathways and thereby elicits the therapeutic intervention.
Stelara Overview
Stelara is marketed for the treatment of several indications in Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Genetic Disorders, Immunology, Metabolic Disorders, and Musculoskeletal Disorders therapy area.
Stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, for the treatment of adult patients (18 years or older) with active psoriatic arthritis (PsA), alone or in combination with methotrexate. Stelara is also indicated for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies, for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant to treatment with one or more TNF blockers, and for the treatment of adult patients with moderately to severely active ulcerative colitis. Stelara is also indicated for the treatment of pediatric patients aged 6 to 11 years with moderate to severe plaque psoriasis. Stelara is also indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
Stelara was first approved in 2008 and is sold globally including the US, the UK, France, Germany, and Japan by several pharma giants including Mitsubishi Chemical Holdings Corp, and Johnson & Johnson. Stelara drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer